BRETEC Intrinsic Valuation and Fundamental Analysis - Bioretec Oy - Alpha Spread
B

Bioretec Oy
OMXH:BRETEC

Watchlist Manager
Bioretec Oy
OMXH:BRETEC
Watchlist
Price: 2.64 EUR -2.58% Market Closed
Market Cap: 53.7m EUR
Have any thoughts about
Bioretec Oy?
Write Note

Intrinsic Value

The intrinsic value of one BRETEC stock under the Base Case scenario is 4.15 EUR. Compared to the current market price of 2.64 EUR, Bioretec Oy is Undervalued by 36%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BRETEC Intrinsic Value
4.15 EUR
Undervaluation 36%
Intrinsic Value
Price
B
Worst Case
Base Case
Best Case

Valuation Backtest
Bioretec Oy

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for BRETEC cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about BRETEC?
Bearish
Neutral
Bullish

Fundamental Analysis

Summary

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Wall St Estimates
Price Target
Loading
Revenue Forecast
Operating Income Forecast
Earnings Forecast
No Indicators Selected
Select Indicators
Investor Returns
Shareholder Yield
Dividend Safety
Dividend Yield
Dividend Payout Ratio
Buyback Yield
Debt Paydown Yield
No Indicators Selected
Select Indicators
Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

AI Assistant
AI Assistant
Ask me anything about Bioretec Oy

Provide an overview of the primary business activities
of Bioretec Oy.

What unique competitive advantages
does Bioretec Oy hold over its rivals?

What risks and challenges
does Bioretec Oy face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Bioretec Oy.

Provide P/S
for Bioretec Oy.

Provide P/E
for Bioretec Oy.

Provide P/OCF
for Bioretec Oy.

Provide P/FCFE
for Bioretec Oy.

Provide P/B
for Bioretec Oy.

Provide EV/S
for Bioretec Oy.

Provide EV/GP
for Bioretec Oy.

Provide EV/EBITDA
for Bioretec Oy.

Provide EV/EBIT
for Bioretec Oy.

Provide EV/OCF
for Bioretec Oy.

Provide EV/FCFF
for Bioretec Oy.

Provide EV/IC
for Bioretec Oy.

Show me price targets
for Bioretec Oy made by professional analysts.

What are the Revenue projections
for Bioretec Oy?

How accurate were the past Revenue estimates
for Bioretec Oy?

What are the Net Income projections
for Bioretec Oy?

How accurate were the past Net Income estimates
for Bioretec Oy?

What are the EPS projections
for Bioretec Oy?

How accurate were the past EPS estimates
for Bioretec Oy?

What are the EBIT projections
for Bioretec Oy?

How accurate were the past EBIT estimates
for Bioretec Oy?

Compare the revenue forecasts
for Bioretec Oy with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Bioretec Oy and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Bioretec Oy against its competitors.

Analyze the profit margins
(gross, operating, and net) of Bioretec Oy compared to its peers.

Compare the P/E ratios
of Bioretec Oy against its peers.

Discuss the investment returns and shareholder value creation
comparing Bioretec Oy with its peers.

Analyze the financial leverage
of Bioretec Oy compared to its main competitors.

Show all profitability ratios
for Bioretec Oy.

Provide ROE
for Bioretec Oy.

Provide ROA
for Bioretec Oy.

Provide ROIC
for Bioretec Oy.

Provide ROCE
for Bioretec Oy.

Provide Gross Margin
for Bioretec Oy.

Provide Operating Margin
for Bioretec Oy.

Provide Net Margin
for Bioretec Oy.

Provide FCF Margin
for Bioretec Oy.

Show all solvency ratios
for Bioretec Oy.

Provide D/E Ratio
for Bioretec Oy.

Provide D/A Ratio
for Bioretec Oy.

Provide Interest Coverage Ratio
for Bioretec Oy.

Provide Altman Z-Score Ratio
for Bioretec Oy.

Provide Quick Ratio
for Bioretec Oy.

Provide Current Ratio
for Bioretec Oy.

Provide Cash Ratio
for Bioretec Oy.

What is the historical Revenue growth
over the last 5 years for Bioretec Oy?

What is the historical Net Income growth
over the last 5 years for Bioretec Oy?

What is the current Free Cash Flow
of Bioretec Oy?

Discuss the annual earnings per share (EPS)
trend over the past five years for Bioretec Oy.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Bioretec Oy

Balance Sheet Decomposition
Bioretec Oy

Current Assets 9.4m
Cash & Short-Term Investments 6.9m
Receivables 1.6m
Other Current Assets 842k
Non-Current Assets 1.3m
PP&E 789k
Intangibles 484k
Current Liabilities 1.8m
Other Current Liabilities 1.8m
Non-Current Liabilities 671k
Long-Term Debt 671k
Efficiency

Earnings Waterfall
Bioretec Oy

Revenue
3.9m EUR
Cost of Revenue
-1.2m EUR
Gross Profit
2.7m EUR
Operating Expenses
-5.8m EUR
Operating Income
-3m EUR
Other Expenses
-755k EUR
Net Income
-3.8m EUR

Free Cash Flow Analysis
Bioretec Oy

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

BRETEC Profitability Score
Profitability Due Diligence

Bioretec Oy's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
ROE is Increasing
Exceptional 1-Year Revenue Growth
28/100
Profitability
Score

Bioretec Oy's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

BRETEC Solvency Score
Solvency Due Diligence

Bioretec Oy's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
87/100
Solvency
Score

Bioretec Oy's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BRETEC Price Targets Summary
Bioretec Oy

Wall Street analysts forecast BRETEC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BRETEC is 3.06 EUR with a low forecast of 3.03 EUR and a high forecast of 3.15 EUR.

Lowest
Price Target
3.03 EUR
15% Upside
Average
Price Target
3.06 EUR
16% Upside
Highest
Price Target
3.15 EUR
19% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for BRETEC?

Click here to dive deeper.

Shareholder Yield

Current shareholder yield for BRETEC is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Want to learn more about BRETEC dividends, buybacks, and debt paydown yield?

Click here to dive deeper.

BRETEC Price
Bioretec Oy

1M 1M
-7%
6M 6M
+8%
1Y 1Y
-1%
3Y 3Y
-10%
5Y 5Y
-10%
10Y 10Y
-10%
Annual Price Range
2.64
52w Low
2.06
52w High
2.94
Price Metrics
Average Annual Return -26.98%
Standard Deviation of Annual Returns 33.31%
Max Drawdown -57%
Shares Statistics
Market Capitalization 52.9m EUR
Shares Outstanding 20 336 859
Percentage of Shares Shorted
N/A

Competitive Landscape

Profile

Bioretec Oy

Country

Finland

Industry

Health Care

Market Cap

52.9m EUR

Dividend Yield

0%

Description

Bioretec Ltd. develops bioabsorbable and bioresorbable implants for pediatric and adult orthopaedics. The company is headquartered in Tampere, Lansi-Suomen. The company went IPO on 2021-09-28. The firm operates as a developer, manufacturer and commercializer of innovative bioresorbable orthopedic implants and implant materials used for the treatment of bone and soft tissue injuries. Bioretec Oy’s existing Activa product portfolio consists of bioabsorbable biopolymer products that are alreadyavailable in the market for applications in pediatrics, trauma surgery as well as sports surgery. Bioretec Oy has one Germany-based subsidiary, BRI.Tech GmbH. The Company’s products are used all over the world.

Contact

LANSI-SUOMEN
Tampere
Yrittajankulma 5
+358207789500
bioretec.com

IPO

2021-09-28

Employees

-

Officers

See Also

Discover More
What is the Intrinsic Value of one BRETEC stock?

The intrinsic value of one BRETEC stock under the Base Case scenario is 4.15 EUR.

Is BRETEC stock undervalued or overvalued?

Compared to the current market price of 2.64 EUR, Bioretec Oy is Undervalued by 36%.

Back to Top